Methyltransferase-like 3 upregulation is involved in the chemoresistance of non-small cell lung cancer.

ABSTRACT:

Background

Treatments for non-small cell lung cancer (NSCLC) have improved tremendously, but therapeutic resistance is a common and major clinical challenge in treatment. Methyltransferase-like 3 (METTL3) is a ribonucleic acid (RNA) methyltransferase that has crucial functions in the development and progression of cancers, including drug resistance, by regulating N6-methyladenosine (m⁶A) modification. However, the role of METTL3 in the progression and drug resistance of NSCLC is poorly understood.

Methods

The expression levels of METTL3 and AKT serine/threonine kinase 1 (AKT1) in NSCLC tissues were detected using quantitative real-time PCR (RT-qPCR), Western blots, and immunohistochemical assays. The m⁶A levels of AKT1 messenger RNA (mRNA) in NSCLC tiss

SUBMITTER: Shi L 

PROVIDER: S-EPMC8904991 | biostudies-literature | 2022 Feb

REPOSITORIES: biostudies-literature